Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
ESMO Congress 2026 · Barcelona, Spain
70 shown of 2,719 total abstracts
  1. Abstract LBA4000LBA2026-09-03 · 20:45 CT · Hall B1
    Long-term follow-up of Opdivo adjuvant for NSCLC: CheckMate-544
    A. Spira, E. Winer · Karolinska Institute
    Plenary SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  2. Abstract LBA4001LBA2026-09-03 · 13:15 CT · Hall B1
    DESTINY-Breast-65: Enhertu (trastuzumab deruxtecan) 2L in NSCLC
    C. Saura, A. Spira, T. Mok, et al. · Stanford Cancer Institute
    Plenary SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  3. Abstract LBA4002LBA2026-09-05 · 13:45 CT · E450
    Biomarker subgroup analysis of Trodelvy in urothelial carcinoma (the ASCENT-598 study)
    M.C. Garassino, H. Borghaei · UCSF Helen Diller Family Comprehensive Cancer Center
    Plenary SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  4. Abstract LBA4003LBA2026-09-05 · 20:30 CT · Arie Crown Theater
    Lynparza plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from OlympiA-480
    C. Saura, S. Antonia, J. Brahmer, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  5. Abstract LBA4004LBA2026-09-03 · 14:15 CT · E450
    Quality of life outcomes with Enhertu in patients with gastric
    G. Curigliano, C. Robert, M.C. Garassino, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Plenary SessionGastrointestinal Cancer📄🖼️
  6. Abstract LBA4005LBA2026-09-01 · 13:15 CT · Arie Crown Theater
    Real-world effectiveness of Verzenio vs standard of care in HR+ breast cancer
    R. Herbst, A. Spira, C. Saura · Memorial Sloan Kettering Cancer Center
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  7. Abstract LBA4006LBA2026-09-01 · 15:00 CT · S406
    Padcev plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from EV-542
    C. Robert, H. Rugo, S. Modi, et al. · Memorial Sloan Kettering Cancer Center
    Plenary SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  8. Abstract LBA4007LBA2026-09-03 · 13:15 CT · E450
    Long-term follow-up of Verzenio maintenance for HR+ breast cancer: MONARCH-637
    M. Reck, J. Cortes, A. Spira, et al. · Dana-Farber Cancer Institute
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  9. Abstract LBA4008LBA2026-09-05 · 14:00 CT · S100A
    ASCENT-111: Trodelvy (sacituzumab govitecan) 3L+ in urothelial carcinoma
    L. Paz-Ares, R. Herbst · Dana-Farber Cancer Institute
    Plenary SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  10. Abstract LBA4009LBA2026-09-04 · 20:30 CT · Hall B1
    IMpower-765: Tecentriq (atezolizumab) maintenance in HCC
    R. Herbst, F. Andre, N. Rizvi, et al. · Peter MacCallum Cancer Centre
    Plenary SessionGastrointestinal Cancer📄🖼️
  11. Abstract LBA4010LBA2026-09-02 · 16:30 CT · S406
    Biomarker subgroup analysis of Imfinzi in biliary tract (the PACIFIC-357 study)
    T. Mok, H. Borghaei · Peter MacCallum Cancer Centre
    Plenary SessionGastrointestinal Cancer📄🖼️
  12. Abstract LBA4011LBA2026-09-02 · 16:00 CT · S406
    Quality of life outcomes with Enhertu in patients with NSCLC
    S. Peters, T. Mok, C. Saura · Chinese University of Hong Kong
    Plenary SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  13. Abstract LBA4012LBA2026-09-04 · 15:45 CT · E450
    Real-world effectiveness of Trodelvy vs standard of care in urothelial carcinoma
    C. Saura, P. Schmid, M. Reck, et al. · Mayo Clinic
    Plenary SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  14. Abstract LBA4013LBA2026-09-03 · 19:45 CT · E450
    Real-world effectiveness of Kisqali vs standard of care in HR+ breast cancer
    E. Winer, C. Saura, S. Tolaney · Chinese University of Hong Kong
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  15. Abstract LBA4014LBA2026-09-04 · 21:00 CT · Hall B1
    Padcev plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from EV-821
    M. Reck, R. Herbst, T. Mok · Chinese University of Hong Kong
    Plenary SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  16. Abstract LBA4015LBA2026-09-03 · 14:45 CT · S406
    Long-term follow-up of Trodelvy 2L for urothelial carcinoma: ASCENT-470
    C. Saura, J. Cortes · Royal Marsden Hospital
    Plenary SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  17. Abstract LBA4016LBA2026-09-02 · 15:45 CT · S406
    Biomarker subgroup analysis of Lynparza in HR+ breast cancer (the OlympiA-9 study)
    P. Schmid, G. Curigliano, C. Robert, et al. · Memorial Sloan Kettering Cancer Center
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  18. Abstract LBA4017LBA2026-09-03 · 21:15 CT · Hall B1
    Quality of life outcomes with Kisqali in patients with HR+ breast cancer
    C. Robert, N. Rizvi, M.C. Garassino, et al. · Dana-Farber Cancer Institute
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  19. Abstract LBA4018LBA2026-09-04 · 19:00 CT · E450
    Long-term follow-up of Trodelvy adjuvant for urothelial carcinoma: ASCENT-762
    S. Tolaney, H. Rugo, S. Antonia, et al. · Stanford Cancer Institute
    Plenary SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  20. Abstract LBA4019LBA2026-09-03 · 14:45 CT · Hall B1
    OlympiA-995: Lynparza (olaparib) neoadjuvant in prostate
    R. Herbst, A. Spira, E. Winer · Johns Hopkins Kimmel Cancer Center
    Plenary SessionGenitourinary Cancer—Prostate📄🖼️
  21. Abstract LBA4020LBA2026-09-03 · 18:30 CT · E450
    CheckMate-294: Opdivo (nivolumab) maintenance in NSCLC
    P. Schmid, C. Saura · MD Anderson Cancer Center
    Plenary SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  22. Abstract LBA4021LBA2026-09-03 · 15:00 CT · Arie Crown Theater
    Long-term follow-up of Enhertu 1L for NSCLC: DESTINY-Breast-37
    T. Mok, S. Peters, E. Winer, et al. · Princess Margaret Cancer Centre
    Plenary SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  23. Abstract LBA4022LBA2026-09-02 · 19:00 CT · S406
    Long-term follow-up of Tecentriq neoadjuvant for TNBC: IMpower-862
    G. Curigliano, C. Robert, S. Tolaney, et al. · Royal Marsden Hospital
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  24. Abstract LBA4023LBA2026-09-05 · 19:30 CT · Hall B1
    Real-world effectiveness of Imfinzi vs standard of care in SCLC
    M. Krop, R. Herbst, H. Borghaei, et al. · Stanford Cancer Institute
    Plenary SessionLung Cancer—Small Cell📄🖼️
  25. Abstract LBA4024LBA2026-09-01 · 21:45 CT · Arie Crown Theater
    Real-world effectiveness of Enhertu vs standard of care in NSCLC
    H. Rugo, C. Robert, H. Borghaei, et al. · Princess Margaret Cancer Centre
    Plenary SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  26. Abstract LBA4025LBA2026-09-02 · 19:00 CT · S100A
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-128
    H. Rugo, S. Antonia, S. Tolaney · National Cancer Center Japan
    Plenary SessionMelanoma📄🖼️
  27. Abstract LBA4026LBA2026-09-03 · 13:15 CT · Hall B1
    Imfinzi plus chemotherapy in previously untreated biliary tract: updated analysis from PACIFIC-401
    T. Mok, E. Winer, F. Andre · Memorial Sloan Kettering Cancer Center
    Plenary SessionGastrointestinal Cancer📄🖼️
  28. Abstract LBA4027LBA2026-09-04 · 16:00 CT · Arie Crown Theater
    Real-world effectiveness of Tagrisso vs standard of care in NSCLC
    M. Krop, M. Reck, F. Andre · Stanford Cancer Institute
    Plenary SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  29. Abstract LBA4028LBA2026-09-05 · 13:15 CT · S406
    Quality of life outcomes with Imfinzi in patients with NSCLC
    A. Spira, T. Mok, R. Herbst, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Plenary SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  30. Abstract LBA4029LBA2026-09-02 · 21:00 CT · S406
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-649 study)
    J. Brahmer, H. Borghaei · Stanford Cancer Institute
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  31. Abstract LBA4030LBA2026-09-04 · 20:30 CT · Hall B1
    Padcev plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from EV-687
    M. Krop, P. Schmid · Cleveland Clinic
    Plenary SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  32. Abstract LBA4031LBA2026-09-04 · 13:15 CT · Arie Crown Theater
    Quality of life outcomes with Trodelvy in patients with TNBC
    S. Modi, G. Curigliano, P. Schmid, et al. · Massachusetts General Hospital
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  33. Abstract LBA4032LBA2026-09-05 · 14:15 CT · S406
    Real-world effectiveness of Lynparza vs standard of care in HR+ breast cancer
    J. Cortes, J. Brahmer, G. Curigliano, et al. · Institut Gustave Roussy
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  34. Abstract LBA4033LBA2026-09-05 · 16:45 CT · S100A
    KEYNOTE-960: Keytruda (pembrolizumab) 3L+ in RCC
    S. Antonia, M. Reck · Princess Margaret Cancer Centre
    Plenary SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  35. Abstract LBA4034LBA2026-09-01 · 20:30 CT · S406
    Padcev plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from EV-198
    M. Reck, H. Rugo, C. Saura, et al. · National Cancer Center Japan
    Plenary SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  36. Abstract LBA4035LBA2026-09-05 · 20:30 CT · Hall B1
    Long-term follow-up of Opdivo 2L for NSCLC: CheckMate-440
    P. Schmid, J. Brahmer · MD Anderson Cancer Center
    Plenary SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  37. Abstract LBA4036LBA2026-09-02 · 13:15 CT · E450
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-60 study)
    T. Mok, C. Robert · Karolinska Institute
    Plenary SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  38. Abstract LBA4037LBA2026-09-01 · 21:45 CT · E450
    Quality of life outcomes with Padcev in patients with urothelial carcinoma
    H. Rugo, G. Curigliano, S. Antonia, et al. · Princess Margaret Cancer Centre
    Plenary SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  39. Abstract LBA4038LBA2026-09-01 · 18:30 CT · S406
    Real-world effectiveness of Trodelvy vs standard of care in TNBC
    S. Peters, J. Cortes, E. Winer, et al. · Princess Margaret Cancer Centre
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  40. Abstract LBA4039LBA2026-09-04 · 19:30 CT · Hall B1
    ASCENT-577: Trodelvy (sacituzumab govitecan) 1L in urothelial carcinoma
    G. Curigliano, M.C. Garassino, H. Rugo, et al. · Johns Hopkins Kimmel Cancer Center
    Plenary SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  41. Abstract LBA4040LBA2026-09-05 · 13:45 CT · Hall B1
    Real-world effectiveness of Padcev vs standard of care in urothelial carcinoma
    A. Spira, J. Brahmer, F. Andre · Stanford Cancer Institute
    Plenary SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  42. Abstract LBA4041LBA2026-09-01 · 20:30 CT · S406
    Enhertu plus chemotherapy in previously untreated NSCLC: updated analysis from DESTINY-Breast-341
    N. Rizvi, M. Reck, J. Brahmer, et al. · Chinese University of Hong Kong
    Plenary SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  43. Abstract LBA4042LBA2026-09-03 · 15:45 CT · S100A
    Real-world effectiveness of Keytruda vs standard of care in SCLC
    C. Saura, N. Rizvi, C. Robert, et al. · Memorial Sloan Kettering Cancer Center
    Plenary SessionLung Cancer—Small Cell📄🖼️
  44. Abstract LBA4043LBA2026-09-02 · 13:45 CT · S406
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-61
    S. Antonia, S. Modi, L. Paz-Ares, et al. · Princess Margaret Cancer Centre
    Plenary SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  45. Abstract LBA4044LBA2026-09-02 · 20:45 CT · Hall B1
    OlympiA-764: Lynparza (olaparib) 3L+ in prostate
    S. Peters, F. Andre, M.C. Garassino, et al. · Peter MacCallum Cancer Centre
    Plenary SessionGenitourinary Cancer—Prostate📄🖼️
  46. Abstract LBA4045LBA2026-09-04 · 15:30 CT · E450
    Biomarker subgroup analysis of Trodelvy in urothelial carcinoma (the ASCENT-638 study)
    J. Cortes, A. Spira, R. Herbst, et al. · Royal Marsden Hospital
    Plenary SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  47. Abstract LBA4046LBA2026-09-01 · 20:00 CT · E450
    Enhertu plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from DESTINY-Breast-68
    R. Herbst, J. Brahmer, F. Andre, et al. · Cleveland Clinic
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  48. Abstract LBA4047LBA2026-09-02 · 18:00 CT · S100A
    Real-world effectiveness of Tecentriq vs standard of care in HCC
    S. Peters, M.C. Garassino, S. Antonia, et al. · University of Chicago
    Plenary SessionGastrointestinal Cancer📄🖼️
  49. Abstract LBA4048LBA2026-09-03 · 19:45 CT · Hall B1
    Keytruda plus chemotherapy in previously untreated RCC: updated analysis from KEYNOTE-547
    H. Rugo, R. Herbst · National Cancer Center Japan
    Plenary SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  50. Abstract LBA4049LBA2026-09-04 · 16:15 CT · S100A
    Real-world effectiveness of Ibrance vs standard of care in HR+ breast cancer
    J. Cortes, S. Modi, R. Herbst · Cleveland Clinic
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  51. Abstract LBA4050LBA2026-09-03 · 13:45 CT · S406
    Long-term follow-up of Lynparza 1L for ovarian: OlympiA-173
    H. Borghaei, E. Winer, H. Rugo, et al. · Massachusetts General Hospital
    Plenary SessionGynecologic Cancer📄🖼️
  52. Abstract LBA4051LBA2026-09-02 · 18:45 CT · S406
    Long-term follow-up of Tagrisso maintenance for NSCLC: FLAURA-279
    F. Andre, G. Curigliano, A. Spira, et al. · Peter MacCallum Cancer Centre
    Plenary SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  53. Abstract LBA4052LBA2026-09-02 · 21:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Opdivo in NSCLC (the CheckMate-880 study)
    M.C. Garassino, H. Borghaei, S. Tolaney · MD Anderson Cancer Center
    Plenary SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  54. Abstract LBA4053LBA2026-09-04 · 14:30 CT · S100A
    EV-306: Padcev (enfortumab vedotin) 3L+ in urothelial carcinoma
    C. Robert, R. Herbst, M.C. Garassino · UCSF Helen Diller Family Comprehensive Cancer Center
    Plenary SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  55. Abstract LBA4054LBA2026-09-05 · 19:00 CT · E450
    Long-term follow-up of Ibrance neoadjuvant for HR+ breast cancer: PALOMA-229
    M.C. Garassino, T. Mok, J. Cortes, et al. · University of Chicago
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  56. Abstract LBA4055LBA2026-09-04 · 20:30 CT · S100A
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-197
    G. Curigliano, E. Winer, H. Rugo · UCSF Helen Diller Family Comprehensive Cancer Center
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  57. Abstract LBA4056LBA2026-09-03 · 15:30 CT · E450
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-564
    G. Curigliano, S. Modi, C. Saura · Peter MacCallum Cancer Centre
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  58. Abstract LBA4057LBA2026-09-02 · 18:45 CT · S100A
    KEYNOTE-612: Keytruda (pembrolizumab) 1L in TNBC
    C. Saura, M. Krop, S. Tolaney, et al. · Stanford Cancer Institute
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  59. Abstract LBA4058LBA2026-09-02 · 16:15 CT · Hall B1
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-45
    N. Rizvi, C. Saura, H. Rugo, et al. · Peter MacCallum Cancer Centre
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  60. Abstract LBA4059LBA2026-09-04 · 21:00 CT · E450
    Long-term follow-up of Keytruda 2L for SCLC: KEYNOTE-523
    S. Peters, M. Krop, M.C. Garassino · Princess Margaret Cancer Centre
    Plenary SessionLung Cancer—Small Cell📄🖼️
  61. Abstract LBA4060LBA2026-09-02 · 18:30 CT · S406
    ASCENT-830: Trodelvy (sacituzumab govitecan) 2L in urothelial carcinoma
    S. Antonia, R. Herbst, C. Robert, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Plenary SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  62. Abstract LBA4061LBA2026-09-03 · 20:00 CT · S406
    Quality of life outcomes with Lynparza in patients with ovarian
    J. Cortes, P. Schmid · Memorial Sloan Kettering Cancer Center
    Plenary SessionGynecologic Cancer📄🖼️
  63. Abstract LBA4062LBA2026-09-04 · 15:45 CT · S100A
    Long-term follow-up of Padcev 2L for urothelial carcinoma: EV-577
    J. Brahmer, M. Reck · Johns Hopkins Kimmel Cancer Center
    Plenary SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  64. Abstract LBA4063LBA2026-09-04 · 16:30 CT · Arie Crown Theater
    Long-term follow-up of Tagrisso maintenance for NSCLC: FLAURA-304
    S. Antonia, J. Brahmer, M. Reck, et al. · Memorial Sloan Kettering Cancer Center
    Plenary SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  65. Abstract LBA4064LBA2026-09-02 · 15:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Imfinzi in SCLC (the PACIFIC-849 study)
    F. Andre, J. Cortes, S. Antonia · UCSF Helen Diller Family Comprehensive Cancer Center
    Plenary SessionLung Cancer—Small Cell📄🖼️
  66. Abstract LBA4065LBA2026-09-04 · 14:30 CT · S406
    DESTINY-Breast-611: Enhertu (trastuzumab deruxtecan) neoadjuvant in NSCLC
    G. Curigliano, M. Reck, H. Borghaei · Memorial Sloan Kettering Cancer Center
    Plenary SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  67. Abstract LBA4066LBA2026-09-01 · 19:45 CT · Arie Crown Theater
    DESTINY-Breast-507: Enhertu (trastuzumab deruxtecan) maintenance in HR+ breast cancer
    P. Schmid, S. Peters, M.C. Garassino, et al. · Princess Margaret Cancer Centre
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  68. Abstract LBA4067LBA2026-09-04 · 18:45 CT · Hall B1
    Biomarker subgroup analysis of Trodelvy in urothelial carcinoma (the ASCENT-836 study)
    F. Andre, J. Cortes, M. Krop, et al. · Mayo Clinic
    Plenary SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  69. Abstract LBA4068LBA2026-09-03 · 13:15 CT · S406
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-401 study)
    S. Tolaney, E. Winer, M. Krop · Mayo Clinic
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  70. Abstract LBA4069LBA2026-09-04 · 16:30 CT · E450
    MONALEESA-631: Kisqali (ribociclib) 2L in HR+ breast cancer
    L. Paz-Ares, S. Antonia · Cleveland Clinic
    Plenary SessionBreast Cancer—Metastatic📄🖼️
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.